The Business

Since 2017, 48HD has raised significant private equity and non-dilutive funding and had 19 revenue generating research and service contracts with pharmaceutical companies and research institutions. Our customers include 5 of the top 20 pharmaceutical companies in the world. The service side of our business generates revenue, with surplus going into internal drug programs.

Internally, 48HD has built a strong technical team capable of executing contracts and building both Cloud and SaaS capacity. Our patented platform attracts established players and generates licensing interest and service contracts from large pharmaceutical companies and research organizations.

Our platform has diverse potential revenue streams across multiple markets. Currently, our contracts are within the drug discovery services market, estimated to be $11B USD in 2020, with a CAGR of about 14% (Market and Markets 2020). We are also developing three internal drug development programs for diseases with multi-billion-dollar market sizes.